Abstract: The invention provides a peptide or a pharmaceutical salt thereof having a length from 14 to 50 and comprising a sequence having at least a 85% of sequence identity with respect to SEQ ID NO: 1, wherein “m”, “n”, “p”, and “q” represent integers and are selected from 0 and 1; the C-terminal end corresponds to —C(O)R4; and N-terminal end corresponds to —NHR5; the peptide optionally comprising a linker biradical “L” of formula (I) connecting an alpha carbon atom of an amino acid located at position “i” with an alpha carbon atom of an amino acid located at position “i+4” or “i+7” in the peptide sequence SEQ ID NO: 1. The present invention also provides fusion proteins and pharmaceutical compositions comprising the peptides of the invention as well as their use in therapy and, particularly, in the treatment of a disease caused by an increase or reduction in VEGF levels.